Omega-3: the mass nutritional deficiency that industry, medicine, and governments are managing badly

The dual architectural and diplomatic role

Each of your 37 trillion cells is surrounded by a membrane. This membrane is not a rigid wall: it is a living, liquid, dynamic film, whose fluidity depends directly on its fatty acid composition. Long-chain omega-3 fatty acids — EPA and DHA — are curved, flexible molecules. Incorporated into membranes, they ensure that receptors move correctly within them, that ion channels open and close at the right moment, that chemical signals pass with precision. A membrane poor in omega-3 is like a window whose mechanism is rusting — it can still open, but with delay, incompletely, at an angle.¹²

The second role of omega-3 is that of inflammation diplomat. From EPA and DHA, the body manufactures molecules called resolvins, protectins, and maresins — specialised pro-resolving mediators. These molecules do not inhibit inflammation as a classical anti-inflammatory would: they actively signal the end of hostilities, order the clearance of cellular debris, and organise tissue repair. Without them, inflammation resolves incompletely — and becomes chronic.³

The plant illusion: ALA is not “omega-3”

This is the first great mystification of modern nutritional discourse, relayed by the agri-food industry with considerable profit.

Omega-3 fatty acids come in three main forms:

• ALA (alpha-linolenic acid): 18 carbons — present in flaxseeds, walnuts, canola, and hemp oils
• EPA (eicosapentaenoic acid): 20 carbons — present in fatty fish, seafood, fish oils
• DHA (docosahexaenoic acid): 22 carbons — same marine sources, major constituent of the brain, retina, and sperm

The plant industry’s argument is that since ALA is the “precursor” of EPA and DHA, consuming flaxseed oil or walnuts is equivalent to consuming “complete” omega-3. This is biologically misleading.

The real conversion figures

⁴⁵⁶

For an adult man, consuming 10 g of flaxseed oil (approximately 5 g of ALA) may produce only 5 to 50 mg of DHA — while the brain alone consumes hundreds of milligrams per day to maintain its neuronal membranes. This conversion is furthermore extremely variable between individuals and strongly suppressed in the presence of a high omega-6/omega-3 ratio, which is precisely the characteristic of Western diet.⁷

“Humans cannot effectively convert ALA (the shortest-chain omega-3, found in some plant, nut and seed oils) into DHA (a longer-chain omega-3 found in fish and seafood) in sufficient quantities to achieve optimal tissue DHA levels.” — FABRI Research Library⁸

A December 2025 study (News-Medical) shows that under strict control of omega-6 intake, ALA supplementation can significantly raise erythrocyte EPA — but the determining factor remains the baseline omega-3 status, not the quantity of ALA ingested. This result, even if optimistic, does not change the fundamental equation: an unsupplemented vegan diet is nearly structurally deficient in cerebral DHA.⁹

What the industry does:

• Labels products “rich in omega-3” as soon as they contain ALA (flaxseed oil added to cereals, omega-3 in vegan biscuits)
• Uses the term “omega-3” generically, without distinguishing ALA, EPA, and DHA
• Promotes vegan diets as nutritionally complete for omega-3 without supplementation

Result: millions of people — vegetarians, vegans, consumers of “omega-3-enriched” plant foods — believe themselves protected while they may be in chronic functional deficiency in DHA and EPA.⁶

Governments: risk management as alibi

The paradox of government recommendations on fish consumption illustrates how institutional liability management can take precedence over public health.

The real contamination

The fatty fish richest in EPA and DHA are indeed contaminated to varying degrees by: methylmercury (neurotoxic, teratogenic), PCBs (endocrine disruptors), dioxins, and PFAS depending on species and fishing zones.

The typical institutional response — Health Canada, the FDA, the WHO — consists of setting mercury thresholds and issuing consumption advisories for pregnant women and children.¹⁰

What these recommendations avoid saying

Health Canada explicitly recognizes in its 2007 assessment that “the beneficial nutrients of selenium and omega-3 fatty acids […] may to some extent counteract the adverse effects of methylmercury.” In other words, authorities know the problem is not binary — but consumption recommendations remain constructed on risk alone.¹¹¹⁰

An analysis published in Environmental Health Perspectives (2011) is direct:

“Nearly all fish consumption advisories for methylmercury are based only on risk. There is a need to also address benefits.”¹¹

The avoided political question

No national health authority asks: why are fish contaminated and what is being done about it? Recommendations are addressed to the individual consumer — “eat less of this fish” — rather than targeting polluting industries or developing clean supply chains. The burden of risk is transferred to the citizen rather than to the polluters.

The silent revolution of cultivated algae

The most elegant solution to this dilemma exists and is rapidly developing — but remains virtually invisible in official recommendations.

The fundamental fact: fish do not produce omega-3. They accumulate them by eating marine microalgae. It is these microalgae that synthesise EPA and DHA from scratch.¹²

Marine microalgae — notably Schizochytrium, Nannochloropsis, Isochrysis, and Phaeodactylum — can be cultivated in closed bioreactors, in sterile conditions, without seawater or a polluted food chain.¹³

Documented advantages:

• Zero mercury, zero PCBs, zero dioxins, zero PFAS¹⁴
• Production of DHA and, depending on the strain, EPA¹⁵
• Lower carbon footprint than traditional fish oil¹³
• Independent of the state of fish stocks
• Bioavailability of algae DHA equivalent to that of fish DHA¹⁴

Companies such as Corbion (AlgaPrime™ DHA), DSM-Firmenich, and Algamega already have products on the market, primarily in aquaculture animal feed but increasingly in direct human nutrition.¹⁵

“Marine microalgae are the original source of marine long-chain Omega-3s DHA and EPA. By growing marine microalgae via fermentation, we produce AlgaPrime™ DHA, an efficient, clean, and sustainable source of long-chain Omega-3s.” — Corbion¹³

What governments could do but don’t: subsidize and regulate access to DHA/EPA supplements from algae cultivated in controlled environments, eliminating the fish-contaminant dilemma for the entire population.

The inflammatory terrain: resolvins, protectins, and maresins

This is the domain where the gap between science and medical practice is widest.

Since the pioneering work of Dr Charles Serhan (Harvard Medical School) in the 2000s, we have known that EPA and DHA are not merely “passive anti-inflammatories” — they are the active precursors of a cascade of pro-resolving lipid mediators:

• E-series resolvins (from EPA): RvE1, RvE2, RvE3
• D-series resolvins (from DHA): RvD1 to RvD6
• Protectins/Neuroprotectins (from DHA): NPD1
• Maresins (from DHA in macrophages): MaR1, MaR2

These molecules instruct macrophages to switch phenotype (from pro-inflammatory to pro-resolving), stimulate efferocytosis (digestion of dead neutrophils and cellular debris), reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and promote tissue repair.³

“Resolvins are thought to be the active metabolites of ω-3 PUFA, and are responsible for facilitating the resolving phase of acute inflammation. Clinically, resolvins have been associated with resolution of acute kidney injury, acute lung injury, micro and macro vascular response to injury, and inhibition of microglia-activated inflammation in neurodegenerative disorders.” — PMC³

The concrete clinical problem: medicine measures inflammation with CRP, IL-6, erythrocyte sedimentation rate — markers of the inflammatory state. It does not measure resolution mediators (resolvins, protectins, maresins), which would inform on the resolving capacity of the organism. A patient with a normal CRP but defective inflammatory resolution can maintain a chronic low-grade inflammation totally invisible in standard blood panels.

Available tests: what is not being measured

The Omega-3 Index: the ignored reference marker

Developed in 2004 by Dr William S. Harris (University of South Dakota, founder of OmegaQuant) and Dr Clemens von Schacky, the Omega-3 Index measures the percentage of EPA+DHA in the membranes of red blood cells relative to total fatty acids.¹⁶¹⁷

It represents a marker of tissue incorporation of omega-3 over the 3 to 4 months preceding the blood draw — the equivalent of HbA1c for glucose.

¹⁸¹⁹¹⁶

The average American sits at 4 to 5% — while the optimal cardioprotective target is 8 to 12%. Similar data exist for Canadian and European populations.²

A pooled analysis of 17 studies covering 42,000 adults in 10 countries showed that individuals with the highest EPA+DHA concentrations had:

• 18% reduction in all-cause mortality
• 20% reduction in cardiovascular mortality
• 13% reduction in cancer mortality²⁰

A US study (US Physicians Health Study) showed that men with the highest index at baseline had a 90% reduction in the risk of sudden cardiac death.²¹

What mainstream medicine measures — or rather, doesn’t

In a standard blood panel, no physician orders an Omega-3 Index. The measurement of membrane fatty acids is in the standard protocols of no specialty — neither cardiology, neurology, psychiatry, rheumatology, nor gastroenterology.²²

Dr Harris himself stated plainly:

“Omega-3s tend to be ignored by the medical community because they belong to the world of nutrition.”²

Available but not routinely used tests:

• Omega-3 Index (EPA+DHA % in red blood cells) — OmegaQuant, Labcorp, and certain specialised Canadian and European laboratories
• Complete membrane fatty acid profile — omega-6/omega-3 ratio, arachidonic acid (AA) levels, DGLA
• EPA/AA ratio — particularly informative for cardiovascular risk and systemic inflammatory status²³
• SPM measurement (resolvins, protectins) — available in research, not yet in routine clinical settings

Conditions where the science-medicine gap is glaring

Psychiatry: solid evidence, persistent indifference

DHA is the major lipid constituent of the prefrontal cortex and grey matter — it represents 40% of polyunsaturated fatty acids in neuronal brain membranes.¹

Established data:

• Depressed patients have reduced EPA and DHA membrane levels in their red blood cells and platelets
• Schizophrenic patients have a significantly lower omega-3 index than the general population
• The 2019 meta-analysis in Translational Psychiatry (Nature), covering 26 randomized controlled trials, confirms the efficacy of omega-3 (EPA-dominant) in depression²⁴
• Bipolar disorder shows DHA deficits in the orbitofrontal cortex, a key region for emotional regulation²⁵
• Studies in prison populations have linked violent behaviours to low omega-3 levels²

“Epidemiological studies indicate an association between depression and low dietary intake of omega-3 fatty acids, and biochemical studies have shown reduced levels of omega-3 fatty acids in red blood cell membranes in both depressive and schizophrenic patients.” — PubMed¹

In mainstream psychiatry, no blood panel measures omega-3. Patients receive antidepressants, antipsychotics, and mood stabilisers without their DHA/EPA status ever having been assessed — and without EPA supplementation being offered as an adjunct, despite the evidence.²⁶²⁷

Cardiovascular disease: the paradox of negative studies

Randomized trials on fish oils have sometimes produced negative results (ORIGIN 2012, some 2018 meta-analyses), interpreted as “omega-3 don’t work” by a large fraction of cardiology.

What these studies failed to measure: the baseline Omega-3 Index. If participants start with an index of 6–7% (typical European or Japanese population), modest supplementation will make little difference. The absence of baseline status measurement is the main reason for contradictory results in the cardiovascular literature.²⁰²³

REDUCE-IT (2019) — with 4 g/day of pure EPA (icosapentaenoic acid at high dose, Vascepa) in hypertriglyceridemic patients — showed a 25% reduction in major cardiovascular events, leading the FDA to approve Vascepa for this indication.²⁸

Autoimmune diseases: the VITAL data

The VITAL randomized trial (25,871 participants, median follow-up 5.3 years), published in the BMJ in 2022, evaluated the effect of vitamin D3 and omega-3 on the incidence of autoimmune diseases:²⁹

• Vitamin D3 alone: 22% reduction (p=0.05)
• Omega-3 alone: 15% reduction (trend, p=0.19)
• Vitamin D3 + omega-3 combined: 31% reduction (p=0.03 — significant)

The authors highlight a time effect for omega-3: the benefit appears to grow with duration, consistent with the notion that progressive membrane incorporation is the active mechanism. A dose of 1,000 mg/day is also low — protection would likely be more pronounced with doses targeting an index of 8%.²⁹

Other documented domains

Why medicine does not act: institutional mechanisms

1. The absence of a lucrative patent. Omega-3 fatty acids are natural molecules that cannot be patented in their standard dietary form. The pharmaceutical industry has no interest in funding mega-trials on fish oil or algae oil. The trials that have been funded were primarily by companies such as AMARIN (for its patentable purified EPA, Vascepa) — hence the bias toward expensive molecules rather than accessible dietary oils.²⁸

2. Medicine of unmeasured biomarkers. Medicine treats what it measures. Cholesterol is measured → statins are prescribed. The omega-3 index is not in blood panels → omega-3 are not prescribed. This is a pure vicious cycle.

3. Guidelines built on poorly designed studies. The major negative studies were conducted without measuring baseline status or the level achieved after supplementation, making causal interpretation impossible. The conclusion “it doesn’t work” became medical orthodoxy without any real basis.²³

4. Capture of recommendations by polluting interests. Fish consumption limitation recommendations protect the industries that pollute the oceans rather than the consumers who need EPA and DHA.

The researchers advancing the field

• Dr William S. Harris, PhD (University of South Dakota, OmegaQuant): creator of the Omega-3 Index (2004), author of over 300 publications, advocating for twenty years for the index to be integrated into standard cardiovascular panels.¹⁷²⁰
• Dr Clemens von Schacky, MD (Ludwig-Maximilian University, Munich; director of Omegametrix): co-developer of the Omega-3 Index, author of the LURIC study on omega-3 and sudden cardiac death.¹⁶
• Dr Charles N. Serhan, PhD (Harvard Medical School): discoverer of resolvins, protectins, and maresins. His work has revolutionized the understanding of inflammation resolution.³⁰³
• Dr Joseph Hibbeln, MD (NIH): specialist in the link between omega-3 and psychiatric disorders, violence, and suicide; international epidemiological studies on fatty fish consumption and depression prevalence.¹
• Dr Artemis Simopoulos, MD (Center for Genetics, Nutrition and Health): specialist in the omega-6/omega-3 ratio — ancestrally 1:1 to 4:1, today 15:1 to 20:1 in Western diets.²⁸

What the state of the oceans requires us to reconsider

The contamination of wild fish is not an immutable constant — it is the result of specific industrial policies. Small fatty fish (sardines, anchovies, herring, mackerel) have far lower contaminant bioaccumulation than large predators (bluefin tuna, swordfish, shark) and remain the best dietary sources of EPA and DHA with a favourable risk-benefit ratio for the vast majority of the population.³⁵¹⁰

The systemic solution requires three simultaneous approaches:

1. Active ocean decontamination and strict regulation of industrial mercury discharges
2. Development of clean aquaculture supply chains fed with microalgae
3. Access to cultivated algae oil supplements in closed environments at affordable prices and reimbursed for at-risk populations

The hope: accessible, measurable, transformative

Functional omega-3 deficiency is possibly the most widespread nutritional deficiency in industrialized countries. An average US index of 4–5% in a population whose cardioprotective target is 8% means that the majority of the population is in the risk zone.²

Clinical advantages:

• Membrane incorporation is measurable and reproducible (Omega-3 Index)
• Documented benefits cover the full spectrum: heart, brain, immunity, inflammation, mental health, fertility, vision
• Clean sources (algae, small fatty fish, molecularly distilled oils) avoid contaminants
• EPA+DHA supplementation at 2 to 4 g/day is considered safe (FDA and EFSA up to 5 g/day)
• Return to an index of 8% is achievable within 3 to 6 months of consistent supplementation

“Every cell in your body has omega-3 in its membranes. If omega-3s are chronically low, your body wears out faster.” — Dr William Harris²

An Omega-3 Index test (available by mail order from OmegaQuant or through certain private Canadian and European laboratories) can reveal within weeks whether cell membranes are being built under the right conditions — or whether they have been functioning in degraded mode for years, without anyone having looked.

Within the framework of the Right to Physiological Integrity, this grounds a right to an optimal EPA and DHA status: the right to recognition of functional deficiency, access to relevant membrane tests, and access to clean, affordable marine omega-3 sources for all.

References